These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12678742)

  • 1. Design of selectively activated anticancer prodrugs: elimination and cyclization strategies.
    Papot S; Tranoy I; Tillequin F; Florent JC; Gesson JP
    Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):155-85. PubMed ID: 12678742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.
    de Groot FM; Loos WJ; Koekkoek R; van Berkom LW; Busscher GF; Seelen AE; Albrecht C; de Bruijn P; Scheeren HW
    J Org Chem; 2001 Dec; 66(26):8815-30. PubMed ID: 11749612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
    Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
    Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
    Leu YL; Roffler SR; Chern JW
    J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
    Tietze LF; Krewer B
    Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard.
    Papot S; Combaud D; Bosslet K; Gerken M; Czech J; Gesson JP
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1835-7. PubMed ID: 10969980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-glucuronidase-mediated drug release.
    de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
    Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
    de Groot FM; van Berkom LW; Scheeren HW
    J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucuronides in anti-cancer therapy.
    Chen X; Wu B; Wang PG
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
    Denny WA; Wilson WR
    J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
    Edupuganti VVSR; Tyndall JDATDA; Gamble AB
    Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.
    Desbene S; Van HD; Michel S; Tillequin F; Koch M; Schmidt F; Florent JC; Monneret C; Straub R; Czech J; Gerken M; Bosslet K
    Anticancer Drug Des; 1999 Apr; 14(2):93-106. PubMed ID: 10405636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast Cyclization of a Proline-Derived Self-Immolative Spacer Improves the Efficacy of Carbamate Prodrugs.
    Dal Corso A; Borlandelli V; Corno C; Perego P; Belvisi L; Pignataro L; Gennari C
    Angew Chem Int Ed Engl; 2020 Mar; 59(10):4176-4181. PubMed ID: 31881115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
    Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
    ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of self-immolative linkers for tumour-activated prodrug therapy.
    Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S
    Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
    Leu YL; Chen CS; Wu YJ; Chern JW
    J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy.
    Devalapally H; Navath RS; Yenamandra V; Akkinepally RR; Devarakonda RK
    Arch Pharm Res; 2007 Jun; 30(6):723-32. PubMed ID: 17679550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
    Akinboye ES; Rosen MD; Bakare O; Denmeade SR
    Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug.
    Schmidt F; Monneret C
    Bioorg Med Chem; 2003 May; 11(10):2277-83. PubMed ID: 12713838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.